Showing results (91-100 of 106) with videos related to
Sort By:
Pageof 11
Bioorganic & Medicinal Chemistry Letters|August 6, 2016
Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical propertiesDavid L Sloman, Njamkou Noucti, Michael D Altman, et al.Stroke|May 25, 2004
Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based studyC J S Price, D K Menon, A M Peters, et al.Archives of Disease in Childhood. Fetal and Neonatal Edition|April 7, 2007
Methicillin-resistant Staphylococcus aureus infections among healthy full-term newbornsL James, R J Gorwitz, R C Jones, et al.Journal of Medicinal Chemistry|April 18, 2024
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 AntagonistEsra Balıkçı, Anne-Sophie M C Marques, Ludwig G Bauer, et al.ACS Medicinal Chemistry Letters|August 25, 2020
Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) InhibitorsQinglin Pu, Hongjun Zhang, Liangqin Guo, et al.ACS Medicinal Chemistry Letters|November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase InhibitorsDerun Li, Hongjun Zhang, Thomas W Lyons, et al.ACS Medicinal Chemistry Letters|September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-OncologyMin Lu, Hongjun Zhang, Derun Li, et al.ACS Medicinal Chemistry Letters|April 16, 2020
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer ImmunotherapyMatthew J Mitcheltree, Derun Li, Abdelghani Achab, et al.Oncoimmunology|April 2, 2021
Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cellsYun Wang, Long Cui, Peter Georgiev, et al.Bioorganic & Medicinal Chemistry Letters|September 1, 2007
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitorsChristopher L Hamblett, Joey L Methot, Dawn M Mampreian, et al.Pageof 11